Abstract |
A series of sulfonamide derivatives, incorporating azabicyclo[3.2.1] octane and phenyl-propyl scaffolds, were prepared by a succession of original steps. The compounds are claimed to act as antagonists of the C-C chemokine receptor 5 (CCR5) involved in the entry of HIV-1 to cells, but only semi-quantitative antiviral data are provided. HIV entry inhibitors, including CCR5 antagonists, are clinically used for the treatment of this viral infection; the compounds claimed in the patent, possessing a new and original scaffold, seem to be of interest for developing novel antiviral agents belonging to this class.
|
Authors | Claudiu T Supuran |
Journal | Expert opinion on therapeutic patents
(Expert Opin Ther Pat)
Vol. 21
Issue 9
Pg. 1491-5
(Sep 2011)
ISSN: 1744-7674 [Electronic] England |
PMID | 21548842
(Publication Type: Journal Article)
|
Chemical References |
- Antiviral Agents
- CCR5 Receptor Antagonists
- HIV Fusion Inhibitors
- Indicators and Reagents
- Sulfonamides
|
Topics |
- Antiviral Agents
(chemical synthesis, pharmacology)
- CCR5 Receptor Antagonists
- HIV Fusion Inhibitors
(chemical synthesis, pharmacology)
- Indicators and Reagents
- Patents as Topic
- Sulfonamides
(chemical synthesis)
|